Obinutuzumab trial for adolescents with active lupus kidney inflammation
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 12 to under 18, or (if recruitment is open) age 5 to under 12
- Your kidney lupus is active Class III or IV on a recent kidney biopsy (within the past 12 months)
- You may also have Class V along with Class III or IV, but isolated Class V alone is not enough
- You have a diagnosis of lupus (SLE) using the SLICC criteria
- Your urine protein is high enough at screening (UPCR above 0.5 from a first-morning urine sample)
- In the last 12 months, you received at least one dose of IV steroid to treat this active lupus kidney episode
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This trial tests a new medicine called O-triple for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if it can control the disease and help protect kidney function.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.